Our short, quick and targeted approach mixes qualitative and quantitative analysis. By applying market data, history, science and quantitative methods; we synthesize metrics of pricing the RegMed universe. RMI incorporates market dynamics, answering crucial questions and generating actionable investment recommendations.
Understanding and knowing the answer as the release is issued requires a historical knowledge of sector pricing to more than “questimate” share perception and rebounds.
August 5, 2019
Regenerative Medicine Earnings Scorecard - Q2/19 - to date
August 5, 2019
RegMed Investors’ (RMi): Worried about Q2 results, think six (6) market factors…
May 19, 2019
Regenerative Medicine Earnings Scorecard - Q1/19 - to date
March 31, 2019
Regenerative Medicine Earnings Scorecard - Q4/18 and FY18 - to date
March 19, 2019
Sage Therapeutics (SAGE) gets FDA approval for Zulresso, a postpartum depression (severe depression after childbirth) therapy
March 12, 2019
Osiris Therapeutics to be acquired for $660 M or +$19 per share by Smith & Nephew
March 11, 2019
BioTime (NYSE American: BTX) closes acquisition of Asterias Biotherapeutics (NYSE American: AST)
February 26, 2019
Ultragenyx Pharmaceutical (RARE) prices a 5.072 M share offering at $60.00
February 26, 2019
Sage Therapeutics (SAGE) prices 3.33 M share offering at $150.00
January 23, 2019
RegMed Investors’ (RMi) mid-day: market forces aren’t the only factor snookering the sector
January 22, 2019
RegMed Investors’ (RMi) mid-day: Editas Medicine (EDIT) CEO Resigns — collapsing gene editing peer group
January 21, 2019
RegMed Investors’ (RMi): worried about 2019, investors better be!
January 16, 2019
Stemline Therapeutics (STML) priced an 8.88 M share offering at $9.00 per share
January 15, 2019
Alnylam Pharmaceuticals (ALNY) priced 5 M share offering at $77.50
December 7, 2018
Global Blood Therapeutics (GBT) Prices a $150 M offering at $44.00 per share
November 23, 2018
Regenerative Medicine Earnings Scorecard - Q3/18 - to date
November 9, 2018
Quarterly (Q3) results special: ADVM, HSGX, BTX, AGTC, ONVO, XON, BLFS, CLBS, PSTI, SGMO, STML and BSTG
November 8, 2018
Quarterly (Q3) results special: ALNY, CRSP, EDIT, OSIR, RGNX, SAGE, VYGR, VSTM and EDIT
November 7, 2018
Quarterly (Q3) results special: ATHX, BOLD, BLCM and GBT
November 6, 2018
Quarterly (Q3) results special: IONS, ONCE, QURE and VCEL
October 31, 2018
Intellia Therapeutics (NTLA) delays and pushes back an anticipated trial of its lead gene editing treatment
October 14, 2018
Verastem Oncology (VSTM) priced a $150 M offering of 5% Convertible Senior Notes in a registered direct offering
October 10, 2018
Audentes Therapeutics (BOLD) proposed a 5.2 M share offering with a 780 K share overallotment priced at $29.00
September 11, 2018
Regenerative Medicine Earnings Scorecard - Q2/18 - to date
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2020 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.